Detailed Information on Publication Record
2004
Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1)
HERMANOVÁ, Markéta, Zdeněk LUKÁŠ, Rudolf NENUTIL, Jan BRÁZDIL, Iva KROUPOVÁ et. al.Basic information
Original name
Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1)
Name in Czech
Amplifikace a overexprese HER-2/neu v invazivních duktálních karcinomech pankreatu a v pankreatických intraepiteliálních neoplaziích a jejich vztah k expresi p21(WAF1/CIP1)
Authors
HERMANOVÁ, Markéta (203 Czech Republic, guarantor), Zdeněk LUKÁŠ (203 Czech Republic), Rudolf NENUTIL (203 Czech Republic), Jan BRÁZDIL (203 Czech Republic), Iva KROUPOVÁ (203 Czech Republic), Leoš KŘEN (203 Czech Republic), Marie PAZOURKOVÁ (203 Czech Republic), Miloš RŮŽIČKA (203 Czech Republic) and Petr DÍTĚ (203 Czech Republic)
Edition
Neoplasma, SLOVAKIA, VEDA, SLOVAK ACADEMY SCIENCES, 2004, 0028-2685
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Slovakia
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 0.822
RIV identification code
RIV/00216224:14330/04:00018978
Organization unit
Faculty of Informatics
UT WoS
000221307400002
Keywords in English
adenocarcinoma; pancreas; HER-2/neu; p21; immunohistochemistry; FISH
Tags
Změněno: 22/6/2009 06:43, prof. MUDr. Markéta Hermanová, Ph.D.
V originále
Overexpression of p21(WAF1/CIP1)seems to be HER-2/neu independent based on our results. Expression of HER-2/neu is growing according to grade of the ductal lesion and overexpression of HER-2/neu was demonstrated in 18% carcinomas. Two of 9 carcinomas with overexpression of HER-2/neu showed the amplification of HER-2/neu.
In Czech
Overexprese p21(WAF1/CIP1) je nezávislá na HER-2/neu dle našich výsledků. Exprese HER-2/neu narůstá podle gradu duktální léze a overexprese HER-2/neu byla prokázána v 18% karcinomů. Jen 2 z 9 karcinomů s overexpresí HER-2/neu měly amplifikaci tohoto genu.